Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions

2021 ◽  
Author(s):  
Ami Rambhia ◽  
Rutul D Patel ◽  
Kennedy E Okhawere ◽  
Talia G Korn ◽  
Ketan K Badani
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Future Directions ◽  
Current Trends

Management of metastatic renal cell carcinoma: current trends

2009 ◽  
Vol 9 (1) ◽  
pp. 75-83 ◽  
Author(s):  
Aza Mohammed ◽  
Iqbal Shergill ◽  
Brian Little
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Current Trends

Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma

2010 ◽  
Vol 10 (3) ◽  
pp. 225-235 ◽  
Author(s):  
J. Ansari ◽  
J. Glaholm ◽  
R. McMenemin ◽  
N.D. James ◽  
S.A. Hussain
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Future Directions ◽  
Recent Advances

scholarly journals Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions

2016 ◽  
Vol 12 (4) ◽  
pp. 533-549 ◽  
Author(s):  
Camillo Porta ◽  
Giampaolo Tortora ◽  
James MG Larkin ◽  
Thomas E Hutson
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Future Directions ◽  
Poor Risk

Emerging Role for Novel Immunotherapy Agents in Metastatic Renal Cell Carcinoma: From Bench to Bedside

2015 ◽  
pp. e291-e297 ◽  
Author(s):  
Matthew Weinstock ◽  
David F. McDermott
Keyword(s):  
Renal Cell Carcinoma ◽  
Immune Response ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Future Directions ◽  
Checkpoint Pathway ◽  
Substantial Clinical Benefit ◽  
Programmed Death ◽  
Immune Response To Cancer

Therapies that augment the antitumor immune response have been an established treatment modality for metastatic renal cell carcinoma (mRCC) since the 1980s. An improved understanding of the factors that limit the immune response to cancer have led to the development of novel therapeutic agents. Most notably, monoclonal antibodies that block the programmed death (PD)-1 immune checkpoint pathway have demonstrated encouraging antitumor activity against mRCC in phase I and II clinical trials. However, as monotherapy these agents are unlikely to offer substantial clinical benefit for the majority of patients with mRCC. Combination approaches and improvements in patient selection will be essential to enhance their efficacy and ensure the rational application of immunotherapy. This review summarizes the clinical and preclinical data that support the use of novel immunotherapies for mRCC and looks forward to future directions for this promising therapeutic strategy.

Sign in / Sign up

Export Citation Format

Share Document